False positive blood tacrolimus concentration in microparticle enzyme immunoassay

被引:19
作者
Homma, M
Tomita, T
Yuzawa, K
Takada, Y
Kohda, Y
机构
[1] Univ Tsukuba, Dept Pharmaceut Sci, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Dept Surg, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan
[3] Tsukuba Univ Hosp, Dept Surg, Dept Pharm, Tsukuba, Ibaraki 3058576, Japan
关键词
false positive; tacrolimus; microparticle enzyme immunoassay; anemia;
D O I
10.1248/bpb.25.1119
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The difference in the blood concentration of tacrolimus between the assay methods, microparticle enzyme immunoassay (MEIA) and enzyme linked immunosorbent assay (ELISA) was observed in a liver transplant recipient with anemia. MEIA provided significantly higher concentration than those of ELISA (7.8+/-1.9 vs. 5.0+/-1.8 ng/ml, p<0.05) while the patient had low haematocrit <25%. The difference, however, was not observed during the periods with haematocrit >25%. This observation suggested that unknown tacrolimus levels generated from difference in assay methods gave incorrect blood tacrolimus during anemia. False positive concentration of tacrolimus ranging 0.1-3.3 ng/ml was observed in MEIA applying to the blood samples obtained from the patients without receiving tacrolimus. The false positive tacrolimus increased in the samples with lower hematocrit, suggesting that MEIA. gave incorrect blood tacrolimus during anemia. Since MEIA potentially overestimates the tacrolimus levels, ELISA should be used for blood tacrolimus monitoring in the patients with anemia.
引用
收藏
页码:1119 / 1120
页数:2
相关论文
共 10 条
[1]   Measurement of tacrolimus (FK506) and its metabolites: A review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies [J].
Alak, AM .
THERAPEUTIC DRUG MONITORING, 1997, 19 (03) :338-351
[2]  
Cao ZT, 1999, CLIN CHEM, V45, P1868
[3]  
Garg UC, 1998, CLIN CHEM, V44, P1783
[4]   Tacrolimus (FK506): Validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study [J].
Lee, JW ;
Sukovaty, RL ;
Farmen, RH ;
Dressler, DE ;
Alak, A ;
Bekersky, I .
THERAPEUTIC DRUG MONITORING, 1997, 19 (02) :201-207
[5]   Chronic anemia as a complication of parvovirus B19 infection in a pediatric kidney transplant patient [J].
Mathias, RS .
PEDIATRIC NEPHROLOGY, 1997, 11 (03) :355-357
[6]   Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels [J].
Sheikh, AM ;
Wolf, DC ;
Lebovics, E ;
Goldberg, R ;
Horowitz, HW .
TRANSPLANTATION, 1999, 68 (02) :307-309
[7]   Weaning of immunosuppression in living donor liver transplant recipients [J].
Takatsuki, M ;
Uemoto, S ;
Inomata, Y ;
Egawa, H ;
Kiuchi, T ;
Fujita, S ;
Hayashi, M ;
Kanematsu, T ;
Tanaka, K .
TRANSPLANTATION, 2001, 72 (03) :449-454
[8]  
VANTHIEL DH, 1995, AM J GASTROENTEROL, V90, P771
[9]  
WALLEMACQ PE, 1993, CLIN CHEM, V39, P2219
[10]  
Wu A, 1998, CLIN TRANSPLANT, V12, P454